Related Experiment Video
Updated: Jun 2, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
Efficiency and safety of prolonged levosimendan infusion in patients with acute heart failure
Georgios Aidonidis1, Ioannis Kanonidis, Vasileios Koutsimanis
1Department of Cardiology, West German Heart Center, Medical School, University of Duisburg-Essen, 45122 Essen, Germany.
Abstract:
Background. Levosimendan is an inotropic drug with unique pharmacological advantages in patients with acute heart failure. Scope of this study is to determine whether longer infusion patterns without the hypotension-inducing loading dose could justify an effective and safe alternative approach. Methods. 70 patients admitted to the emergencies with decompensated chronic heart failure received intravenously levosimendan without a loading dose up to 72 hours. Clinical parameters, BNP (Brain Natriuretic Peptide) and signal-averaged-ECG data (SAECG) were recorded up to 72 hours. Results. The 48-hour group demonstrated a statistically significant BNP decrease (P < .001) after 48 hours, which also maintained after 72 hours. The 72-hour group demonstrated a bordeline decrease of BNP after 48 hours (P = .039), necessitating an additional 24-hour infusion to achieve significant reduction after 72 hours (P < .004). SAECG data demonstrated a statistically significant decrease after 72 hours (P < .04). Apart from two deaths due to advanced heart failure, no major complications were observed. Conclusion. Prolonged infusion of levosimendan without a loading dose is associated with an acceptable clinical and neurohumoral response.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure Drugs: Inotropic Agents
Heart Failure VI: Adjunct Therapies
Cardiomyopathy V: Interprofessional Care
Heart Failure III: Clinical Manifestations
Heart Failure Drugs: Diuretics